Alerts will be sent to your verified email
Verify Email
None
|
Agilus Diagnostics
|
Jagsonpal Pharma
|
Hamps Bio
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
11.26 % | 12.82 % | 17.75 % |
|
5yr average Equity Multiplier
|
1.21 | 1.29 | 2.66 |
|
5yr Average Asset Turnover Ratio
|
0.64 | 1.12 | 1.39 |
|
5yr Avg Net Profit Margin
|
13.83 % | 8.95 % | 5.48 % |
|
Price to Book
|
n/a | 6.1 | 0.0 |
|
P/E
|
n/a | 26.44 | 57.2 |
|
5yr Avg Cash Conversion Cycle
|
-88.59 Days | -0.27 Days | 10.22 Days |
|
Inventory Days
|
12.46 Days | 47.66 Days | 38.15 Days |
|
Days Receivable
|
38.81 Days | 25.88 Days | 49.29 Days |
|
Days Payable
|
132.35 Days | 68.7 Days | 79.37 Days |
|
5yr Average Interest Coverage Ratio
|
17.09 | 56.07 | 3.3 |
|
5yr Avg ROCE
|
10.64 % | 17.0 % | 22.28 % |
|
5yr Avg Operating Profit Margin
|
20.3 % | 10.5 % | 15.08 % |
|
5 yr average Debt to Equity
|
0.0 | 0.02 | 1.2 |
|
5yr CAGR Net Profit
|
-4.89 % | 23.34 % | 33.03 % |
|
5yr Average Return on Assets
|
9.37 % | 9.97 % | 7.45 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
n/a | 67.78 % | 71.99 % |
|
Share Pledged by Promoters
|
n/a | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
n/a | -0.93 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
n/a | 0.0 | 0.0 |
|
Agilus Diagnostics
|
Jagsonpal Pharma
|
Hamps Bio
|
|---|